USA

Under the definitive agreement, which both companies’ boards unanimously approved, Vertex will pay US$85.00 in cash for each outstanding Crinetics share.

The acquisition gives Zimmer Biomet full ownership of the iovera° system, an FDA-cleared medical device that relieves pain without medication.

The OPUSWAVE Imaging System is built around Terumo’s DualView Imaging Catheter, which combines optical frequency-domain imaging (OFDI) and intravascular ultrasound (IVUS) on a single platform.

The company has announced plans to expand its antibody-drug conjugate (ADC) manufacturing capabilities in Switzerland while also broadening its long-term partnership with a leading, though undisclosed, U.S.-based biopharmaceutical company.

The combined business will operate as Cortigent Holdings and trade on Nasdaq under the ticker symbol CRGT once the transaction closes, expected in the third quarter of 2026, subject to shareholder and regulatory approvals.

Researchers can use the platform to design CRISPR screening experiments, analyse single-cell RNA sequencing data and generate three-dimensional protein structures, chemistry drawings and genome browser tracks.

The agreement brings together Lilly’s expertise in developing innovative medicines with Abu Dhabi’s advanced healthcare infrastructure, population-scale health data, and genomics capabilities.

The new site will serve as the company’s U.S. global headquarters and future manufacturing centre as it accelerates the development of targeted cancer therapies.

Biogen has paused or discontinued funding for most of Apellis’ legacy research portfolio while conducting a comprehensive review of the acquired company’s clinical and preclinical assets.

Developed by Geneoscopy and offered commercially through Labcorp, ColoSense is intended for adults aged 45 to 85 years who are considered to have an average risk of colorectal cancer.